» Articles » PMID: 19898501

Pre-transplant Risk Factors Affecting Outcome in Hurler Syndrome

Overview
Specialty General Surgery
Date 2009 Nov 10
PMID 19898501
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Allogeneic transplantation remains the standard of care for patients with Hurler syndrome. As enzyme replacement therapy (ERT) has become available, controversy has emerged in regards to whether the use of enzyme in the peri-transplant period is appropriate. An analysis was performed on 74 patients with Hurler syndrome transplanted at the University of Minnesota between 1990 and 2003, before our use of ERT associated with transplant, with the intention of determining if patients at higher risk during the transplant can be identified based on evaluations and events before transplantation. Age, the presence of hydrocephalus, a history of cardiovascular issues or upper airway obstruction before transplant was not associated with significant differences in survival. In contrast, patients who had a history of lower airway disease, including reactive airway disease or bronchiolitis, or a history of pneumonia, had a significantly inferior outcome based on OS. The risk for serious respiratory complications was also assessed by evaluating the incidence of intubation. Overall, 31% of these patients were intubated. The risk of intubation was higher in older patients and in those with a history of lower airway disease. These findings have implications for the care of patients with high-risk features.

Citing Articles

Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation.

Carbajal-Rodriguez L, Perez-Garcia M, Rodriguez-Herrera R, Rosales H, Olaya-Vargas A Heliyon. 2021; 7(8):e07740.

PMID: 34458603 PMC: 8379671. DOI: 10.1016/j.heliyon.2021.e07740.


The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury.

Zinter M, Lindemans C, Versluys B, Mayday M, Sunshine S, Reyes G Blood. 2021; 137(12):1679-1689.

PMID: 33512420 PMC: 7995292. DOI: 10.1182/blood.2020009246.


Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R Biol Blood Marrow Transplant. 2019; 25(7):e226-e246.

PMID: 30772512 PMC: 6615945. DOI: 10.1016/j.bbmt.2019.02.012.


Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison.

Eisengart J, Rudser K, Xue Y, Orchard P, Miller W, Lund T Genet Med. 2018; 20(11):1423-1429.

PMID: 29517765 PMC: 6129229. DOI: 10.1038/gim.2018.29.


Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience.

Rodgers N, Kaizer A, Miller W, Rudser K, Orchard P, Braunlin E J Inherit Metab Dis. 2017; 40(2):271-280.

PMID: 28054207 DOI: 10.1007/s10545-016-0006-2.